期刊文献+

C端带His标签重组ScFv真核表达载体的构建及鉴定 被引量:1

Construction and identification of ScFv eukaryotic expression vectors with His-tag at C terminal
下载PDF
导出
摘要 目的:构建表达抗p185且含His标签的ScFv的真核表达载体。方法:通过PCR自pcDNAH520C9ScFv-hIL-2质粒中获得H520C9ScFv片段,将此片段插入真核表达质粒pcDNA3.1(+)中;设计引物在ScFv片段C端增加His标签和凝血酶识别序列,再与质粒pcDNA3.1(+)连接,将所得的融合基因进行限制性内切酶EcoR I、HindⅢ双酶切及琼脂糖凝胶电泳鉴定,并测定目的序列。结果:成功将H5200C9ScFv片段、His标签和凝血酶识别序列插入真核表达质粒pcDNA3.1(+)中。结论:成功构建了真核表达载体pcDNA3.1-His-ScFv,为下一步在真核细胞中表达和纯化抗p185单抗奠定基础。 Objective:To construct the ScFv eukaryotic expression vector with His-tag at C-terminal which possessed anti-p185 properties. Methods: The H520CgsFv fragment was derived from the pcDNA-H520CgScFv- hIL-2 plasmid by polymerase chain reaction and inserted into the eukaryotic expression plasmid pcDNA3.1 ( + ). The primers were designed to allow for addition of the His label and the thrombin-recognizing sequence to the C- terminal of ScFv, which entailed insertion into the eukaryotic expression vector pcDNA3.1 ( + ). The fusion gene was subject to EcoR I and Hind Ⅲ restriction enzyme digestion and agarose gel electrophoresis for sequencing of the targeted fragment. Results: The H520CgsFv fragment, His label and the thromhin-recognizing sequence have been successfully inserted into the eukaryotic expression vector pcDNA3.1 ( + ). Conclusion: The successful construction of the eukaryotic expression vector peDNA3.1-His-ScFv provides a solid basis for further research on expression and purification of anti-p185 monoclonal antibodies in eukaryotie cells.
出处 《广州医学院学报》 2013年第5期13-16,共4页 Academic Journal of Guangzhou Medical College
基金 广州市卫生局项目(20121A011140) 广州市科技计划项目(2009J1-C371-1)
关键词 载体构建 His标签 融合基因 乳腺肿瘤 Construction of vector ScFv His tag fusion gene breast cancer
  • 相关文献

参考文献14

  • 1Jemal A,Thomas A,Murray T,et al.Cancer Statistics 2002[J].CA Cancer J Clin,2002,52(1):23-47.
  • 2Graus-Porta D,Beerli RR,Daly JM,et al.ErbB-2,the preferred heterodimerization partner of all ErbB receptor,is a mediator of lateral signaling[J].EMBO J,1997,16(7):1647-1655.
  • 3Busse D,Doughty RS,Arteaga CL.HER-2/neu(erbB-2) and the cell cycle[J].Semin Oncol,2000,27(6 Suppl 11):3-8.
  • 4Slamon DJ,Clark GM,Wong SG,et al.Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene[J].Science,1987,235(4785):177-182.
  • 5Slamon D,Godophin W,Jones L,et al.Studies of HER-2/neu proto-oncogene in human breast and ovarien cancer[J].Science,1989,244(4905):707-712.
  • 6Hynes NE,Stern DF.The biology of erbB-2/neu/HER-2 and its role in cancer[J].Biochim Biophys Acta,1994,1198(2-3):165-184.
  • 7Recillion F,Bonneterre J,Peyrat JP.ERBB2 oncogene in human breast cancer and its clinical significance[J].Eur J Cancer,1998,34(6):791-808.
  • 8Holliger P,Hudson PJ.Engineered antibody fragments and the rise of single domains[J].Nat Biotechnol,2005,23(9):1126-1136.
  • 9Pavlinkova G,Colcher D,Booth BJ,et al.Pharmacokinetics and biodistribution of a light-chain-shuffled CCA9 single-chain Fv antibody construct[J].Cancer Immunol Immunother,2000,49(4-5):267-275.
  • 10Li J,Gyorffy SF,Ring DB,et al.Preparation and characterization of a recombinant humanized single-chain Fv antibody/human interleukin-2 fusion protein directed against the HER-2/neu(c-erbB2) proto-oncogene product,p185[J].Tumor Targ,1999,4(2):105-114.

共引文献1

同被引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部